Kiss; Szilard
Patent Applications and Registrations
Patent applications and USPTO patent grants for Kiss; Szilard.The latest application filed is for "methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept".
- Kiss; Szilard - New York NY
| Patent | Date |
|---|---|
| Methods of treating CMV retinitis by T cell therapy Grant 11,103,577 - O'Reilly , et al. August 31, 2 | 2021-08-31 |
| Methods Of Treating Ocular Neovascular Diseases Using Aav2 Variants Encoding Aflibercept App 20210100856 - GASMI; Mehdi ; et al. | 2021-04-08 |
| Methods of Treating CMV Retinitis by T Cell Therapy App 20200016261 - O'Reilly; Richard John ; et al. | 2020-01-16 |
| Methods of treating CMV retinitis by T cell therapy Grant 10,342,864 - O'Reilly , et al. July 9, 2 | 2019-07-09 |
| Methods of Treating CMV Retinitis by T Cell Therapy App 20170128565 - O'Reilly; Richard John ; et al. | 2017-05-11 |
| Virus-mediated Delivery Of Bevacizumab For Therapeutic Applications App 20150182638 - Crystal; Ronald G. ; et al. | 2015-07-02 |
| Virus-mediated Delivery Of Bevacizumab For Therapeutic Applications App 20130090375 - Crystal; Ronald G. ; et al. | 2013-04-11 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 